Anne Wojcicki Net Worth: From Billion-Dollar Genomics Pioneer to Tech Industry

Anne Wojcicki, a trailblazing figure in consumer health technology, has seen her fortunes rise and fall alongside the company she co-founded—23andMe. Once considered a transformative force in biotech, Wojcicki was at the helm of a company that changed the way people understood their genetics. But as of 2025, her estimated net worth stands at $150 million, a significant drop from her peak when her paper wealth exceeded $500 million.

Wojcicki’s journey is not only a story of innovation but also a powerful reflection of the volatility in the tech-health startup space.

Early Life and Academic Roots

Born on July 28, 1973, in Palo Alto, California, Anne Wojcicki grew up in the heart of Silicon Valley in a family driven by education and science. Her father, Stanley Wojcicki, was a Stanford physics professor, while her mother, Esther Wojcicki, was a renowned educator and journalist.

Anne is the youngest of three sisters—her siblings include Susan Wojcicki, former CEO of YouTube, and Janet Wojcicki, an epidemiologist. The family’s intellectual environment shaped Anne’s early interest in biology and public health. She attended Yale University, where she majored in biology and played varsity ice hockey, graduating in 1996.

Career Origins: From Wall Street to Health-Tech Visionary

After college, Wojcicki worked as a healthcare investment analyst. But rather than following the money, she became disillusioned with the healthcare system’s emphasis on short-term profits. This experience sparked her desire to create something that would put power back into the hands of the individual.

In 2006, she co-founded 23andMe with the mission of offering direct-to-consumer genetic testing—a groundbreaking concept at the time. Consumers could purchase a kit, send in a saliva sample, and receive detailed ancestry and health-related DNA insights.

The product was quickly hailed as revolutionary, with Time Magazine naming it the Invention of the Year in 2008. Wojcicki emphasized public participation in health research, encouraging customers to opt in to data sharing to fuel future medical breakthroughs.

23andMe’s Meteoric Rise

23andMe’s influence surged in the 2010s. In 2015, the company became the first to receive FDA approval for at-home health-related genetic testing, a key turning point. Three years later, it inked a $300 million deal with GlaxoSmithKline, allowing the pharma giant access to anonymized user data for drug development.

This partnership attracted both praise and criticism. While it showcased the scientific potential of aggregated health data, privacy advocates raised concerns about consent and data control. Nonetheless, the deal solidified 23andMe’s growing influence in the biotech sphere.

In 2021, the company went public via a SPAC merger with VG Acquisition Corp, led by Richard Branson. The deal raised $600 million and initially valued 23andMe at $3.5 billion, with Anne Wojcicki’s 9% stake theoretically worth $540 million at the height of the stock’s performance.

From Unicorn to Bankruptcy

Despite the early excitement on Wall Street, 23andMe struggled to maintain momentum. The company remained unprofitable, failed to diversify revenue, and couldn’t convert its genetic database into successful drug therapies at scale.

The company initiated multiple layoffs starting in 2022, and by early 2024, its stock price had dropped over 99%, prompting a NASDAQ delisting threat. On March 24, 2025, 23andMe filed for bankruptcy, and Anne stepped down as CEO the same day.

By then, 23andMe’s market cap had plummeted to just $20 million, and Anne’s remaining stake was valued at roughly $1.8 million—a shocking fall from her once-billion-dollar company valuation.

Personal Life and High-Profile Relationships

Anne Wojcicki’s personal life has also attracted media attention over the years. In 2007, she married Google co-founder Sergey Brin, with whom she has two children. Although the couple divorced in 2015, they remain active co-parents and have collaborated on philanthropic efforts through the Brin Wojcicki Foundation.

In 2016, Anne briefly dated former MLB star Alex Rodriguez, a relationship that sparked headlines as they were spotted together at several tech and sports events.

Philanthropy and Advocacy

Despite business setbacks, Anne has continued to focus on giving back. Through her foundation with Brin, she has supported causes ranging from Parkinson’s research to immigrant support programs and educational initiatives like Wikipedia.

She also played a crucial role in democratizing access to health data and advocating for customer-led medical research, opening up conversations about consent, ethics, and the power of data in medical innovation.

Legacy in Health-Tech Innovation

Anne Wojcicki’s legacy is more than just 23andMe’s financial rollercoaster. She pioneered the direct-to-consumer genetic testing model, influenced FDA policy, and challenged traditional health systems to prioritize personal empowerment.

While her net worth today sits at $150 million, a far cry from the peaks of the early 2020s, Anne’s reputation as a visionary in biotech remains intact. Her work set the stage for a wave of personalized medicine startups and a shift in how consumers view health ownership.

What’s Next for Anne Wojcicki?

As of now, Wojcicki has remained quiet about her next moves following 23andMe’s collapse. Given her track record, it’s likely she’ll either return with a new health-tech venture or dive deeper into philanthropy and public health advocacy.

At 51 years old, with a strong network, industry experience, and still substantial personal wealth, Anne Wojcicki’s story isn’t over—it’s entering its next chapter.

Whether as a founder, investor, or public health advocate, her influence on modern medicine is already cemented—and what comes next could be just as disruptive.